Peptide Half-Life Explained (and Why It Varies So Much)
Half-life comes up constantly in peptide research discussion and is frequently misused. It is a specific pharmacokinetic concept, it varies enormously across this compound class, and understanding why explains a lot about how different peptides are studied. This is conceptual background — it is not a schedule and not a recommendation.
What half-life actually means
Half-life is the time taken for the concentration of a substance in circulation to fall by half. It is a property of the molecule and the body processing it, not a setting anyone chooses.
It is also not the same as duration of effect. A compound can be cleared quickly while its downstream effects persist, and the reverse can also be true. Conflating the two is the most common error in how the term gets used.
Why peptides vary so wildly
Native peptides are generally short-lived — sometimes minutes — because the body is extremely efficient at breaking down amino-acid chains. Enzymes called peptidases exist specifically to do this.
That is a problem for research and for drug development, so a great deal of engineering effort goes into extending it. The differences you see between compounds are largely the result of those modifications rather than anything intrinsic.
How half-life gets extended
Several strategies appear across the compounds discussed on this site. Acylation attaches a fatty-acid chain that binds albumin in circulation, effectively parking the molecule; this is the approach behind the long-acting GLP-class compounds. DAC — a drug affinity complex — does something comparable and is why CJC-1295 with DAC behaves so differently from CJC-1295 without it.
Amino-acid substitution replaces residues that peptidases target, and cyclisation or capping the ends protects against enzymes that attack chain termini.
Why "with DAC" matters on a label
This is the practical case where the distinction bites. CJC-1295 with DAC and CJC-1295 without DAC (sometimes sold as Mod GRF 1-29) are handled very differently in published research precisely because their half-lives differ by orders of magnitude. The reconstitution maths is identical; nothing else is. Always confirm which version a vial contains.
What half-life does not tell you
It does not tell you how much to use, how often, or whether a compound is appropriate for anything. It is one property among many, and published research protocols account for far more than clearance rate. Treat it as background for understanding why compounds are studied differently — not as an input to a schedule.
Where it touches the maths
Indirectly. A compound studied at frequent intervals will get through a vial faster than one studied less often, which affects how many draws you need from a vial and therefore what vial size and dilution make sense. The calculator shows draws-per-vial so you can plan around that.
Key takeaways
- Half-life is time for circulating concentration to halve — not duration of effect.
- Native peptides are short-lived; peptidases break amino-acid chains efficiently.
- Acylation and DAC extend half-life by binding albumin — hence long-acting variants.
- CJC-1295 with vs without DAC differ enormously; confirm which your vial is.
